Experimental drug auxora tested in critical COVID-19 lung patients

NCT ID NCT04661540

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small Phase 2 trial tested an experimental drug called Auxora in 10 patients with critical COVID-19 pneumonia who were on ventilators. The goal was to see how the drug affected immune cells in the lungs and to check its safety. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Auxora (CM4620-IE)

What this could lead to

If successful, Auxora could help control severe immune reactions in critical COVID-19 pneumonia, potentially improving outcomes for ventilated patients.

What could go wrong

This was a very small, early-phase trial (only 10 participants) that was terminated early, so results are limited. The drug may not show clear benefit or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19 pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States